- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
CytoSorb® approved by the EU to remove rivaroxaban, a Factor Xa inhibitor
May 13, 2020
MigVax appoints Eyal Desheh, former Teva, Check Point executive, as chairman
Jun 09, 2020
Progenics and Curium Announced European Collaboration for Prostate Cancer Imaging Agent PyL
Sep 03, 2019
Amid bitter trade war, U.S. companies pledge millions of dollars in aid
Feb 07, 2020
Innovent and Lilly Collaborate to Advance Novel Medicines
Feb 09, 2026
Newleaf Brands Announces Newest Newleaf Brands Advisor Appointee, Dr. Aubrey Oliver, set to Spearhead Jamaican-based Psilocybin Healing Retreat Efforts
May 26, 2020
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
Mar 20, 2020
Follow us on
